Encyclopedia of Medical Immunology

Living Edition
| Editors: Ian MacKay, Noel R. Rose

DADA2

  • Amanda K. OmbrelloEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9209-2_118-1
  • 2 Downloads

Synonyms

Definition

The deficiency of adenosine deaminase type 2 (DADA2) is an autosomal recessive disease resulting from biallelic, loss-of-function mutations in ADA2 (formerly known as CECR1), located in chromosome 22q11.1. DADA2 is characterized by systemic vasculitis and features of both autoinflammation and immunodeficiency (MIM#615688).

Introduction and Background

DADA2 was initially reported in 2014 in patients who presented with inflammatory phenotypes that resembled vasculitis and polyarteritis nodosa (PAN) and recurrent ischemic and/or hemorrhagic strokes (Zhou et al. 2014; Navon Elkan et al. 2014). Since the initial publications, the clinical phenotype has expanded significantly to include additional disease manifestations. The identification of DADA2 expands the family of adenosine deaminase-related diseases from the most commonly known severe combined immune...

This is a preview of subscription content, log in to check access.

References

  1. Ben-Ami T, Revel-Vilk S, Brooks R, et al. Extending the clinical phenotype of adenosine deaminase 2 deficiency. J Pediatr. 2016;177:316–320.CrossRefGoogle Scholar
  2. Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J. 2016;14:51.CrossRefGoogle Scholar
  3. Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognized cause of early onset polyarteritis nodosa and stroke: a multicenter national study. Ann Rheum Dis. 2017;76:1648–56.CrossRefGoogle Scholar
  4. Hashem H, Kumar AR, Müller I, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological and vascular phenotype in DADA2. Blood. 2017;130:2682–8.CrossRefGoogle Scholar
  5. Michniacki TF, Hannibal M, Ross CW, et al. Hematologic manifestations of deficiency of adenosine deaminase 2 (DADA2) and response to tumor necrosis factor inhibition in DADA2-associated bone marrow failure. J Clin Immunol. 2018;38:166–73.CrossRefGoogle Scholar
  6. Nanthapisal S, Murphy C, Omoyinmi E, et al. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol. 2016;68:2314–22.CrossRefGoogle Scholar
  7. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370:921–31.CrossRefGoogle Scholar
  8. Ombrello AK, Qin J, Hoffmann P, et al. Treatment strategies for the deficiency of adenosine deaminase 2. N Engl J Med. 2019;380:1582–4.CrossRefGoogle Scholar
  9. Pichard DC, Ombrello AK, Hoffmann P, Stone DL, Cowen EW. Early-onset stroke, polyarteritis nodosa (PAN), and livedo racemosa. J Am Acad Dermatol. 2016;75:449–53.CrossRefGoogle Scholar
  10. Sahin S, Adrovic A, Barut K, Ugurlu S, Turanli E, Ozdogan H, Kasapcopur O. Clinical, imaging and genotypical features of three deceased and fiver surviving cases with ADA2 deficiency. Rheumatol Int. 2018;38(1):129–136.CrossRefGoogle Scholar
  11. Schepp J, Proietti M, Frede N, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69:1689–700.CrossRefGoogle Scholar
  12. Trotta L, Martelius T, Siitonen T, et al. ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol. 2018;141:1534–7.CrossRefGoogle Scholar
  13. Vu D, Gonzalez RG, Schaefer PW. Conventional MRI and MR angiography of stroke. In: Gonzalez RG, Hirsch JA, Koroshetz WJ, Lev MH, Schaefer P, editors. Acute ischemic stroke: imaging and intervention. Berlin: Springer; 2006. p. 115–37.CrossRefGoogle Scholar
  14. Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391:51–7.CrossRefGoogle Scholar
  15. Zavialov AV, Garcia E, Glaichenhaus N, et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88:279–90.CrossRefGoogle Scholar
  16. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370:911–20.CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

Authors and Affiliations

  1. 1.National Human Genome Research Institute, National Institutes of HealthBethesdaUSA

Section editors and affiliations

  • Raphaela Goldbach-Mansky
    • 1
  1. 1.Translational Autoinflammatory Diseases Section (TADS)National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)BethesdaUSA